Brief: XBiotech Announces Discovery That Blocking Interleukin-1A Reduces Brain Injury And Neurological Deficit After Stroke
14/07/2020 16:49
July 14 (Reuters) - XBiotech Inc XBIT.O :
* XBIOTECH ANNOUNCES DISCOVERY THAT BLOCKING INTERLEUKIN-1A
REDUCES BRAIN INJURY AND NEUROLOGICAL DEFICIT AFTER STROKE
* XBIOTECH INC - PLANS TO ENTER INTO HUMAN CLINICAL STUDIES
WITH A
NEW PRODUCT CANDIDATE FOR STROKE IN 2021
Source text for Eikon: urn:newsml:reuters.com:*:nGNX6V5mxH
Further company coverage: XBIT.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on XBiotech
See all newsBrief: XBiotech Announces Positive Final Efficacy Results From Phase II Taskin Trial
Brief: Xbiotech Launches Phase Ii Clinical Trial Evaluating Vilamakitug For The Treatment Of Active Axial Spondyloarthritis
Brief: Xbiotech Launches Phase Ii Clinical Trial Evaluating Vilamakitug For The Treatment Of Active Axial Spondyloarthritis
Brief: XBiotech Inc - John Simard To Retire As CEO Of XBiotech - SEC Filing
Brief: Xbiotech Announces Enrollment Completion Of Phase I Clinical Trial For Hutrukin, A Novel Candidate Therapy For Stroke